Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study
media
posted on 2021-04-13, 14:27 authored by Adis journals on behalf of, Philip J. Mease, Apinya Lertratanakul, Kim A. Papp, Filip E. van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W. Keiserman, Xianwei Bu, Liang Chen, Reva M. McCaskill, Patrick Zueger, Erin L. McDearmon-Blondell, Aileen L. Pangan, William Tillett<p><strong>Article full text</strong></p>
<p><br>
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.
</p>
